Insider · CIK 0001821956
Abbas Hussain
Files at Keenova Therapeutics plc, MRNA (Moderna, Inc.). First filing Jun 12, 2025, latest Jun 12, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MRNA: Moderna, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 5Weak | Moderna, Inc. | $8,736 312 shares | -35% | +17% from low-65% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2025 | MRNA Moderna, Inc. | SOpen-market sale Common Stock10b5-1 | -312 | $28.00 | $8,736 | 580 | Jun 12, 2025 |
| Apr 30, 2025 | MRNA Moderna, Inc. | MOption exercise Common Stock | +892 | - | - | 892 | May 1, 2025 |
| Apr 30, 2025 | MRNA Moderna, Inc. | MOption exercise Restricted Stock Unitsderivative | -892 | $0.00 | $0 | 0 | May 1, 2025 |
| Apr 30, 2025 | MRNA Moderna, Inc. | AGrant or award Restricted Stock Unitsderivative | +16,233 | $0.00 | $0 | 16,233 | May 1, 2025 |
| Jan 1, 2025 | - Keenova Therapeutics plc | MOption exercise Ordinary Shares | +1,504 | - | - | 1,504 | Jan 2, 2025 |
| Jan 1, 2025 | - Keenova Therapeutics plc | FTax withholding Ordinary Shares | -324 | - | - | 1,180 | Jan 2, 2025 |
| Jan 1, 2025 | - Keenova Therapeutics plc | DDisposition to issuer Restricted Stock Unitsderivative | -1,231 | - | - | 6,976 | Jan 2, 2025 |
| Jan 1, 2025 | - Keenova Therapeutics plc | MOption exercise Restricted Stock Unitsderivative | -1,504 | $0.00 | $0 | 5,472 | Jan 2, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.